303 related articles for article (PubMed ID: 30635887)
21. Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Bazzoli F; Zagari RM; Pozzato P; Fossi S; Ricciardiello L; Nicolini G; De Luca L; Berretti D; Alampi G; Di Pietro C; Morelli P; Roda E
Aliment Pharmacol Ther; 2002 Jan; 16(1):153-8. PubMed ID: 11856090
[TBL] [Abstract][Full Text] [Related]
22. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Kawai T; Takahashi S; Suzuki H; Sasaki H; Nagahara A; Asaoka D; Matsuhisa T; Masaoaka T; Nishizawa T; Suzuki M; Ito M; Kurihara N; Omata F; Mizuno S; Torii A; Kawakami K; Ohkusa T; Tokunaga K; Mine T; Sakaki N
J Gastroenterol Hepatol; 2014 Dec; 29 Suppl 4():29-32. PubMed ID: 25521730
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
Su J; Zhou X; Chen H; Hao B; Zhang W; Zhang G
Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with
Mokhtare M; Nikkhah M; Behnam B; Agah S; Bahardoust M; Masoodi M; Faghihi A
Indian J Pharmacol; 2020; 52(4):266-271. PubMed ID: 33078727
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
[TBL] [Abstract][Full Text] [Related]
26. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
[TBL] [Abstract][Full Text] [Related]
27. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: Findings from a single-centre randomized clinical trial in population of Pakistan.
Waqar F; Noor M; Haider E; Farhat K; Ali S; Fatime Gilani SF
J Pak Med Assoc; 2024 Mar; 74(3):432-435. PubMed ID: 38591272
[TBL] [Abstract][Full Text] [Related]
29. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Francavilla R; Lionetti E; Castellaneta SP; Magistà AM; Boscarelli G; Piscitelli D; Amoruso A; Di Leo A; Miniello VL; Francavilla A; Cavallo L; Ierardi E
Gastroenterology; 2005 Nov; 129(5):1414-9. PubMed ID: 16285942
[TBL] [Abstract][Full Text] [Related]
30. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.
Nishida T; Tsujii M; Tanimura H; Tsutsui S; Tsuji S; Takeda A; Inoue A; Fukui H; Yoshio T; Kishida O; Ogawa H; Oshita M; Kobayashi I; Zushi S; Ichiba M; Uenoyama N; Yasunaga Y; Ishihara R; Yura M; Komori M; Egawa S; Iijima H; Takehara T
World J Gastroenterol; 2014 Apr; 20(15):4362-9. PubMed ID: 24764674
[TBL] [Abstract][Full Text] [Related]
31. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
Nista EC; Candelli M; Zocco MA; Cazzato IA; Cremonini F; Ojetti V; Santoro M; Finizio R; Pignataro G; Cammarota G; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2005 May; 21(10):1241-7. PubMed ID: 15882245
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.
Sardarian H; Fakheri H; Hosseini V; Taghvaei T; Maleki I; Mokhtare M
Helicobacter; 2013 Apr; 18(2):129-34. PubMed ID: 23121338
[TBL] [Abstract][Full Text] [Related]
33. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.
Lee H; Kim BJ; Kim SG; Kim JI; Choi IJ; Lee YC; Kim JG; Kim JJ;
Trials; 2017 Nov; 18(1):549. PubMed ID: 29149904
[TBL] [Abstract][Full Text] [Related]
34. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Georgopoulos S; Papastergiou V; Xirouchakis E; Laoudi F; Lisgos P; Spiliadi C; Papantoniou N; Karatapanis S
J Clin Gastroenterol; 2013 Mar; 47(3):228-32. PubMed ID: 22858517
[TBL] [Abstract][Full Text] [Related]
35. Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Grgov S; Tasić T; Radovanović-Dinić B; Benedeto-Stojanov D
Vojnosanit Pregl; 2016 Nov; 73(11):1044-9. PubMed ID: 29328644
[TBL] [Abstract][Full Text] [Related]
36. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.
Tan B; Luo HQ; Xu H; Lv NH; Shi RH; Luo HS; Li JS; Ren JL; Zou YY; Li YQ; Ji F; Fang JY; Qian JM
PLoS One; 2017; 12(4):e0175625. PubMed ID: 28407007
[TBL] [Abstract][Full Text] [Related]
37. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
38. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.
Paoluzi OA; Visconti E; Andrei F; Tosti C; Lionetti R; Grasso E; Ranaldi R; Stroppa I; Pallone F
J Clin Gastroenterol; 2010 Apr; 44(4):261-6. PubMed ID: 20195162
[TBL] [Abstract][Full Text] [Related]
39. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
Qian J; Ye F; Zhang J; Yang YM; Tu HM; Jiang Q; Shang L; Pan XL; Shi RH; Zhang GX
Helicobacter; 2012 Dec; 17(6):478-85. PubMed ID: 23067317
[TBL] [Abstract][Full Text] [Related]
40. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H
Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
